Australia Continuous Glucose Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Australia continuous glucose monitoring market size in 2026 is estimated at USD 207.8 million, growing from 2025 value of USD 178.21 million with 2031 projections showing USD 448.08 million, growing at 16.61% CAGR over 2026-2031. This report is Segmented by Individual Components, Such As Sensors and Durables (receivers and Transmitters) and by Provinces. The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

Australia Continuous Glucose Monitoring Market Trends and Insights

Rapidly Increasing Diabetes Prevalence

Australia’s diagnosed diabetes population rose to 1.5 million adults in 2024, equal to 6.6% of residents, up from 5.1% a decade earlier. Type 2 diabetes represents 1.2 million of these cases, yet full NDSS CGM subsidies still apply only to 130,000 Type 1 patients, creating a gap that policy makers are addressing. Indigenous Australians face diabetes rates three times the national average, and the Waminda pilot showed that 18 of 25 Aboriginal women achieved glycemic improvement using CGM plus group visits, with 7 attaining remission. Parliamentary committees are therefore recommending subsidy expansion to high-risk insulin-dependent Type 2 and gestational cohorts, a step that could double the eligible patient pool by 2027. Employers in mining and resources are also piloting on-site CGM programs that cut high-risk worker counts by more than half, indicating commercial willingness to fill coverage gaps.

Advances in CGM Sensor Technology

Factory-calibrated sensors with mean absolute relative difference (MARD) below 10% have become the country standard, removing the need for finger-stick confirmation. Abbott’s FreeStyle Libre 3 posts a 7.9% MARD, while Dexcom G7 records 8.2% overall and 8.6% in pediatric users, comfortably inside Therapeutic Goods Administration non-adjunctive dosing criteria. Wear time now extends to 14 days, halving annual sensor counts and supporting adherence. Real-time Bluetooth feeds to smartphones enable predictive alerts and caregiver sharing, features that drive uptake in children and older adults. Medtronic’s Simplera all-in-one disposable sensor, launched globally in 2024, promises easier insertion and lower cost once TGA approval is secured. These advances collectively keep Australia continuous glucose monitoring market growth on a steep trajectory.

High Device and Consumable Cost

Unsubsidized Australians face annual CGM bills of AUD 3,000-5,000 (USD 1,980-3,300), confining uptake among 1.2 million Type 2 patients to under 5%. Even with NDSS support, transmitters and app fees can top AUD 500 (USD 330) yearly, burdening pensioners and low-income households. Abbott, Dexcom, and Medtronic dominate supply, limiting price competition, while parallel-import rules block cheaper overseas sourcing. Some employers offset costs through wellness schemes, but coverage remains inconsistent. NDSS distribution tenders also force suppliers to maintain temperature-controlled networks across a vast continent, adding 15-20% to logistics expenses and constraining aggressive price cuts.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of NDSS Reimbursement Policies
• Integration with Hybrid Closed-Loop Insulin Systems
• Logistics Barriers to Serve Remote Regions

Segment Analysis

Sensors generated 82.28% of Australia continuous glucose monitoring market revenue in 2025, and the segment is projected to maintain a double-digit trajectory as NDSS eligibility expands and factory-calibrated 14-day wear becomes the norm. Abbott’s Libre 3 and Dexcom G7 both pair smaller footprints with rapid 30-minute warmup, encouraging upgrades that buoy average selling prices even as unit counts decline. Australia continuous glucose monitoring market size for sensors is forecast to climb to USD 365.9 million in 2031, implying a 16.02% CAGR alongside steady subsidy inflows.

Durables - transmitters and receivers - represented the remaining 17.72% in 2025, yet they are forecast to outpace sensors at 17.05% CAGR, reaching USD 82.18 million by 2031 as hybrid closed-loop systems create mandatory hardware refresh cycles. Transmitter evolution toward Bluetooth Low Energy now extends battery life to three months, while smartphone apps are cannibalizing standalone receivers, leaving a niche among seniors and remote users who lack smartphones. Medtronic’s Simplera could disrupt segment boundaries by integrating transmitter elements into the disposable sensor if TGA approval arrives in 2026, potentially reshaping Australia continuous glucose monitoring market share dynamics among incumbents.

Complete Report Scope:

• By Component
  • Sensors
  • Transmitters
  • Receivers
• By End User
  • Hospitals / Clinics
  • Home / Personal
• By Demography
  • Adult
  • Pediatric

List of Companies Covered in this Report:

• Abbott Laboratories
• Dexcom
• Medtronic
• Ascensia Diabetes Care Holdings AG
• Roche
• Insulet

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support